Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ARTHNASDAQ:TMDINASDAQ:XAIR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$1.14-3.4%$1.95$0.39▼$18.00$5.40M3.535,995 shs316 shsTMDITitan Medical$0.14-26.3%$0.23$0.13▼$1.20$15.67M2.364.83 million shs7.71 million shsXAIRBeyond Air$1.21$1.66$1.14▼$6.36$43.61M-0.18306,143 shs357,278 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics-3.39%+2.01%-46.73%-70.08%-62.00%TMDITitan Medical0.00%0.00%0.00%0.00%0.00%XAIRBeyond Air0.00%-9.02%-23.42%-11.03%-79.21%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATMDITitan MedicalN/AN/AN/AN/AN/AN/AN/AN/AXAIRBeyond Air3.1357 of 5 stars3.50.00.03.51.10.81.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch TherapeuticsN/AN/AN/AN/ATMDITitan MedicalN/AN/AN/AN/AXAIRBeyond Air3.00Buy$11.25829.75% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K67.55N/AN/A($2.43) per share-0.47TMDITitan Medical$20.09M0.78N/AN/A$0.32 per share0.44XAIRBeyond AirN/AN/AN/AN/A$1.40 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98MN/A0.00∞N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)TMDITitan Medical-$14.86M-$0.19N/A∞N/AN/A-167.03%-112.15%N/AXAIRBeyond Air-$55.82M-$2.13N/AN/AN/AN/A-199.90%-106.00%6/27/2024 (Estimated)Latest ARTH, TMDI, and XAIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/20/2024Q1 2024ARTHArch TherapeuticsN/A-$0.57-$0.57-$0.57N/A$0.05 million2/12/202412/31/2023XAIRBeyond Air-$0.61-$0.50+$0.11-$0.50$0.49 million$0.39 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/ATMDITitan MedicalN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.160.04TMDITitan MedicalN/A1.411.41XAIRBeyond Air0.613.393.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%TMDITitan Medical3.55%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%TMDITitan Medical0.02%XAIRBeyond Air19.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics84.74 million4.53 millionNot OptionableTMDITitan Medical49111.95 million111.93 millionNot OptionableXAIRBeyond Air9836.04 million29.19 millionOptionableARTH, TMDI, and XAIR HeadlinesSourceHeadlineBeyond Paradise's dating storyline is a breath of fresh airdigitalspy.com - April 12 at 6:47 PMBeyond the Horizon Air and Space Show ends with record number of spectatorsmsn.com - April 10 at 1:56 PMBeyond the Horizon Air Show attracts thousands to Maxwell AFBwsfa.com - April 7 at 2:22 PMBeyond Air (NASDAQ:XAIR) Trading 3.2% Higher marketbeat.com - April 5 at 12:43 AMBeyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock?zacks.com - March 21 at 1:01 PMBeyond Air Prices Direct Offering Of $16 Mln Of Shares, Warrantsmarkets.businessinsider.com - March 20 at 6:51 PMBeyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrantsglobenewswire.com - March 20 at 9:00 AM"There is a great need to look for mobility alternatives and we are going to operate with electric vehicles in the air"lapoliticaonline.com - March 18 at 11:59 PMBeyond Paradise star teases a different side to her character in season 2yahoo.com - March 16 at 11:37 PMWill Renewed Nvidia Excitement Lift the Entire Market?realmoney.thestreet.com - February 23 at 10:34 AMBed Bath & Beyond has a new CEO, air quality’s rising impact on real estate and moreyahoo.com - February 20 at 5:50 PMBeyond Air (XAIR) Earnings Dates & Reportsinvesting.com - February 13 at 10:29 PMBeyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcriptmsn.com - February 13 at 12:27 PMRecap: Beyond Air Q3 Earningsbenzinga.com - February 12 at 9:23 PMBeyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimatesmsn.com - February 12 at 9:23 PMBeyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024finance.yahoo.com - February 12 at 4:22 PMBeyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024finance.yahoo.com - February 12 at 4:22 PMA Preview Of Beyond Air's Earningsbenzinga.com - February 9 at 2:21 PMAI model gives air quality forecasts that are similar to weather forecastsmsn.com - February 3 at 10:01 PMBeyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcastfinance.yahoo.com - January 18 at 1:43 PMBeyond Air Inc (XAIR) may enjoy gains as insiders got busy in the recent daysknoxdaily.com - January 2 at 12:58 PMMedical Device Player Beyond Air's Subsidiary Reveals Encouraging Data From Early-Stage Cancer Studymsn.com - December 27 at 12:25 PMBeyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumorsfinance.yahoo.com - December 27 at 12:25 PMBeyond Air Independent Director Acquires 102% More Stockfinance.yahoo.com - December 23 at 9:57 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArch TherapeuticsOTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Titan MedicalNASDAQ:TMDITitan Medical, Inc. engages in the research and development of a computer-assisted robotic surgical technology for application in minimally invasive surgery (MIS). Its portfolio, the Enos™ system, is a robotic single access surgery with dual 3D and 2D definition vision systems, multi-articulating instruments, and a surgeon workstation. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada.Beyond AirNASDAQ:XAIRBeyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
